Peter Madrid is a Co-Founder & Head of Scientific Development at Synfini, inc. based in San Francisco, California, United States, North America. My professional career has been focused on developing new therapeutics and diagnostics for infectious diseases with unmet medical needs. My expertise is on advancing new anti-infective and anti-cancer drugs from target selection through lead optimization and clinical candidate nomination. As the lead principal investigator on NIH- and DoD-funded research programs, I have developed new classes of therapeutic compounds, as well as new technologies that accelerate drug discovery. This includes screening assay design, high-throughput screening, hit-to-lead identification and lead optimization. Currently, I'm the Director of the Discovery Technologies group at SRI International, where I oversee the finances, operations, business development and strategic planning for a group of multidisciplinary scientists. Accomplishment highlights: • Developing a new class of anti-TB drugs with the potential to shorten the length of therapy and treat multi-drug resistant infections • Developing a simple, inexpensive high-throughput screening assay against the antibiotic drug target gyrase B • Identifying antiviral compounds from drug re-purposing screens with activity against Ebola virus in animal models • Developing a rapid bacterial diagnostic test that can simultaneously determine the type of bacteria and its drug susceptibility profile from a minimal sample
Current Position: Co-Founder & Head of Scientific Development
Company: Synfini, inc.
Location: San Francisco, California, United States, North America
Social: Professional profiles available
Network: Extensive professional connections